For decades, nicotine regulation has been built upon laboratory science, toxicological assessments, and clinical research. These forms of evidence remain indispensable for understanding product chemistry, biological mechanisms, and potential health effects. Yet as smoke-free nicotine products continue to evolve, regulators are increasingly recognising that scientific evidence alone does not always explain how products perform in everyday life.
This is where real-world evidence (RWE) has become an increasingly important part of regulatory decision-making.
For GINN, evidence-based policymaking should draw upon the full spectrum of available scientific knowledge. Laboratory testing, clinical trials, and toxicological assessments each answer important questions, but they are only part of the picture. Understanding how products are actually used by consumers, how regulations influence behaviour, and whether public health objectives are achieved requires evidence generated beyond controlled research settings.
Looking Beyond the Laboratory
Controlled studies remain the cornerstone of scientific evaluation. They provide regulators with robust information on product composition, toxicant exposure, pharmacology, and potential health effects under carefully managed conditions. However, real-world behaviour is rarely as controlled as a clinical trial.
Adult smokers do not all switch in the same way. Some transition completely to smoke-free alternatives, while others reduce cigarette consumption gradually before making a full switch. Consumer preferences vary according to nicotine strength, flavour, product format, accessibility, and affordability. These behavioural differences can significantly influence public health outcomes and cannot always be predicted from laboratory data alone.
Real-world evidence helps bridge this gap by examining how products perform outside research environments and within everyday society.
Why Real-World Evidence Matters
Increasingly, policymakers are asking questions that laboratory science alone cannot answer. Does a particular regulatory measure encourage smokers to move away from combustible cigarettes? Does it unintentionally create barriers to switching? How do packaging requirements influence consumer understanding? What effect do flavour restrictions have on adult purchasing behaviour? Are youth protection measures delivering their intended outcomes?
These are questions of public health policy rather than product chemistry.
Real-world evidence allows regulators to observe patterns of use across large populations, monitor behavioural trends over time, and evaluate whether regulatory interventions are achieving their objectives. Rather than relying solely on theoretical assumptions, policymakers are able to assess outcomes as they occur within real communities and regulated markets.
Importantly, real-world evidence is not limited to quantitative data. It also includes the lived experiences of people who have used smoke-free nicotine products as part of their journey away from combustible cigarettes. These experiences provide valuable insight into why individuals switch, how they navigate challenges, and what factors influence long-term success or relapse.
Lived Experience: Understanding Behaviour Beyond the Data
One of the greatest strengths of real-world evidence is that it captures experiences that cannot easily be measured in laboratory or clinical settings. Qualitative studies consistently show that many adults describe vaping products and nicotine pouches as practical, acceptable alternatives that helped them reduce or move away from smoking, often outside formal cessation programmes.
Many participants describe gradual transitions rather than immediate change. Some reduce the number of cigarettes they smoke before switching completely, while others continue using smoke-free products over the longer term to help avoid relapse. Across these experiences, common themes emerge: products that fit naturally into daily routines, provide satisfactory nicotine delivery, and are socially acceptable are frequently reported as supporting sustained movement away from combustible cigarettes.
These experiences do not replace clinical evidence, nor do they demonstrate that every smoker will achieve the same outcome. Rather, they help explain how and why people use these products in everyday life, offering insights that are often absent from controlled trials. They also remind policymakers that successful regulation should be informed not only by product characteristics, but by the realities of consumer behaviour.
Complementing Clinical Research
Importantly, real-world evidence should not be viewed as competing with clinical research. The strongest regulatory decisions are informed by multiple sources of evidence working together.
Laboratory science explains what a product contains and how it behaves chemically. Clinical studies investigate its effects under carefully controlled conditions. Real-world evidence then provides insight into how those findings translate into everyday public health outcomes.
Taken together, these complementary forms of evidence provide a more comprehensive understanding than any individual study could achieve in isolation.
This increasingly integrated approach reflects how regulatory science is evolving across many areas of healthcare and consumer product regulation, including smoke-free nicotine products.
Informing Risk-Proportionate Regulation
The growing importance of real-world evidence also supports a broader shift toward risk-proportionate regulation.
Not all nicotine products present the same level of risk, nor do all regulatory interventions produce identical public health outcomes. Policies that are effective for combustible tobacco may not necessarily produce the same results when applied to smoke-free nicotine products.
By examining actual consumer behaviour and population-level outcomes, real-world evidence enables regulators to evaluate whether policies reduce youth uptake, support adult smokers who are seeking alternatives to combustible cigarettes, improve public understanding of relative risk, or unintentionally encourage illicit markets.
This continuous evaluation strengthens regulatory decision-making by allowing policies to evolve alongside emerging evidence rather than remaining fixed to assumptions made before implementation.
A More Dynamic Approach to Regulation
As nicotine regulation becomes increasingly sophisticated, regulators are recognising that policymaking should not end once legislation is introduced. Effective regulation requires ongoing monitoring, review, and refinement.
Real-world evidence provides this feedback mechanism. It enables policymakers to identify emerging trends, assess whether regulations remain proportionate, and respond to new scientific findings as markets and consumer behaviour continue to evolve.
This adaptive approach is particularly important for novel nicotine products, where innovation continues to outpace traditional regulatory cycles.
Looking Ahead
The future of nicotine governance will depend not only on strong scientific research but also on understanding how regulation performs in practice.
For GINN, real-world evidence should be regarded as an essential complement to laboratory and clinical science. This includes both population-level data and the lived experiences of adults who have successfully transitioned away from combustible cigarettes. Together, these complementary sources of evidence provide a richer understanding of how smoke-free nicotine products are used, how regulation influences behaviour, and how public health objectives can best be achieved.
As governments continue reviewing smoke-free nicotine products, the most effective regulatory frameworks will be those informed by both scientific evidence and real-world outcomes. Only by considering both can policymakers develop regulation that is evidence-based, proportionate, and responsive to the realities of modern nicotine use.
